Compare MRDN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRDN | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.1M | 173.4M |
| IPO Year | 2008 | 2020 |
| Metric | MRDN | FHTX |
|---|---|---|
| Price | $11.11 | $1.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $19.73 | $9.89 |
| AVG Volume (30 Days) | 51.2K | ★ 997.2K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $182,863,373.00 | $30,909,000.00 |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $10.93 | $15.98 |
| P/E Ratio | $33.00 | ★ N/A |
| Revenue Growth | 21.01 | ★ 36.75 |
| 52 Week Low | $6.01 | $1.79 |
| 52 Week High | $16.09 | $7.61 |
| Indicator | MRDN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.24 | 12.33 |
| Support Level | $9.99 | N/A |
| Resistance Level | $14.87 | $5.35 |
| Average True Range (ATR) | 0.61 | 0.28 |
| MACD | -0.27 | -0.16 |
| Stochastic Oscillator | 3.80 | 6.51 |
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.